Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 2Gastrointestinal 2Tumor-Agnostic 1Other hematologic neoplasm 1NET 1Head & Neck 1Gynecologic 1Genitourinary 1Endocrine 1CNS 1

Conditions

Neuroendocrine Tumors 1

Interventions

lutetium Lu 177 dotatate 14Specimen Handling 8Magnetic Resonance Spectroscopy 8Everolimus 8cabozantinib 6pembrolizumab 4Nivolumab 4olaparib 3lenvatinib 3X-Rays 3Lutetium-177 3Cyclophosphamide 3177Lu-octreotide, DOTA(0)-Tyr(3)- 3lanreotide 2gallium Ga 68 dotatate 2fludarabine phosphate 2fludarabine 2avelumab 2amino-acid, glucose, and electrolyte solution 2Sunitinib 2Phantoms, Imaging 2Octreotide 2Ipilimumab 2Fluorodeoxyglucose F18 23-aminopyridine-2-carboxaldehyde thiosemicarbazone 2tivozanib 1surufatinib 1repotrectinib 1peposertib 1pazopanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
peposertib × NET × 90 days × Clear all
NCT04750954 2026-05-13

Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors

National Cancer Institute (NCI)

Phase 1 Active not recruiting
29 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡